Key Takeaways
- The potential impact of the IRS’s new guidance regarding management contracts and other similar arrangements under Rev. Proc. 97-13
- Health system and payer mergers, affiliations and integration trends for 2015
- Merger and affiliation models and the impact on existing capital structures and access to capital
- New Master Trust Indenture models
- The evolution of the direct placement market
- Lessons learned from the SEC’s recent MCDC initiative and its enforcement efforts
- Recent tax-exempt bond structuring models and the potential effect of rising interest rates
- Use of taxable debt in the health care sector
- Living with the Municipal Advisor rule
Speakers
- David Y. Bannard, Partner, Foley & Lardner LLP
- Christine Doyle, Managing Director, The PFM Group
- Jim Moloney, Managing Director, Cain Brothers
- Roger D. Strode, Partner, Foley & Lardner LLP
People
Related Insights
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.
11 March 2025
Consumer Class Defense Counsel
No Harm, No Foul: Greenwashing Lawsuit Dismissed for Lack of Article III Standing
It is well-settled that under Article III of the Constitution, United States federal courts are limited to trying “cases and controversies.”